RxDoctor Payments Data

Sonali Ganguly, MD

Endocrinology, Diabetes & Metabolism · Suwanee, GANPI 1215666862

Payments from drug & device makers

$4,142in general payments, 2019–2025

Across 116 payments — averaging $35.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Lilly USA, LLC$486
  • Novo Nordisk$424
  • Xeris Pharmaceuticals, Inc.$358
  • AbbVie$95
  • Insulet Corporation$90
  • plus $706 from 16 others

What the payments were for

  • Travel & lodging$1,21829%
  • Food & beverage$2,88170%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,142 in reported general payments places this provider in the 55th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia

Medicare billing

Part B allowed, 2024
$50,322
Medicare patients
205
Services billed
1,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide148$167,468
TrulicityDulaglutide117$114,565
JardianceEmpagliflozin116$87,185
Tresiba Flextouch U-200Insulin Degludec40$57,318
FarxigaDapagliflozin Propanediol58$44,719
MounjaroTirzepatide33$43,393
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/718$11,796
JanuviaSitagliptin Phosphate11$11,282
TradjentaLinagliptin11$8,457
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$8,067
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$5,744
Novolog FlexpenInsulin Aspart36$4,761
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm24$3,733
SynthroidLevothyroxine Sodium56$3,694
NovologInsulin Aspart12$3,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$424$170,810160 claims
Lilly USA, LLCTrulicity, Mounjaro$486$157,958150 claims
Boehringer IngelheimJardiance, Tradjenta$56$95,643127 claims
AstraZenecaFarxiga$45$44,71958 claims
AbbVieSynthroid$95$3,69456 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

Other endocrinology, diabetes & metabolism in Suwanee

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →